The Journal of Korean Medicine (대한한의학회지)

The Society of Korean Medicine (대한한의학회)
권호 표지

Synergic Effect of GamiSamgieum (SGMX) and Lipitor on Hyperlipidemia in Animal Model

  • Park, Hye-Jung (Internal Department of Oriental Medicine College, Daejeon University) ;
  • Seol, In-Chan (Internal Department of Oriental Medicine College, Daejeon University) ;
  • Son, Chang-Gue (Internal Department of Oriental Medicine College, Daejeon University)
  • Published : 2009.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: To investigate the possibility of GamiSamgieum (SGMX) as a combination therapy with statins on hyperlipidemia using an animal model. Methods: Forty eight ICR mice (male) were divided into six groups of eight mice each: naive, induced, Lipitor 5 mg/kg, Lipitor 5 mg/kg plus SGMX 100 mg/kg, Lipitor 10 mg/kg, and Lipitor 10 mg/kg plus SGMX mg/kg treatment group. Hyperlipidemia was induced by feeding a purified high fat diet for all groups (except naive) along with treatment of drugs for 6 weeks, and then biological parameters were examined on the last experiential day. Results: Lipitor treatment lowered total cholesterol and increased HDL-cholesterol compared to the induced group with no statistical significance. However, co-treatment of SGMX with Lipitor revealed synergic effects on total cholesterol and HDL-cholesterol significantly (P < 0.05) in both. SGMX co-treatment also significantly protected liver tissues from the oxidative stress in liver tissues (P < 0.05) and augmented inhibitory effect of Lipitor against fat accumulation in the body. Conclusion: These results indicate the possibility of that SGMX can be used for patients having hyperlipidemia as a combination therapy with statin drugs.

Keywords

References

  1. Jain KS, Kathiravan MK, Somani RS, Shishoo CJ. The biology and chemistry of hyperlipidemia. Bioorg Med Chem. 2007; 15(14):4674-99. https://doi.org/10.1016/j.bmc.2007.04.031
  2. Rosen IM, Sams RW 2nd. Common questions in managing hyperlipidemia. Prim Care. 2006; 33(4):903-21. https://doi.org/10.1016/j.pop.2006.09.007
  3. Fowler SB, Kelly M, Ruh D, Johnson-Wells D. Management of lipid disorders for stroke prevention. J Neurosci Nurs. 2006; 38:282-7. https://doi.org/10.1097/01376517-200609000-00003
  4. Keenan JM. Treatment of patients with lipid disorders in the primary care setting: new treatment guidelines and their implications. South Med J. 2003; 96(3):266-75. https://doi.org/10.1097/01.SMJ.0000061513.59902.6A
  5. Havel RJ, Rappaport E. Management of primary hyper-lipidemia. N Engl J Med. 1995; 332:14491-9.
  6. Huang TL, Chen JF. Cholesterol and lipids in depression: stress, hypothalamo-pituitary-adrenocortical axis, and inflammation and immunity. Adv Clin Chem. 2005; 39:81-105. https://doi.org/10.1016/S0065-2423(04)39003-7
  7. Wierzbicki AS, Mikhailidis DP, Wray R. Drug treatment of combined hyperlipidemia. Am J Cardiovasc Drugs. 2001; 1(5):327-36. https://doi.org/10.2165/00129784-200101050-00003
  8. Walsh JM, Pignone M. Drug treatment of hyperlipidemia in women. JAMA. 2004; 291(18):2243-52. https://doi.org/10.1001/jama.291.18.2243
  9. Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol. 1998; 82(4B):3-10. https://doi.org/10.1016/S0002-9149(98)00769-3
  10. Steinmetz KL, Schonder KS. Colesevelam: potential uses for the newest bile resin. Cardiovasc Drug Rev. 2005 Spring; 23(1):15-30. https://doi.org/10.1111/j.1527-3466.2005.tb00154.x
  11. Gupta RS, Pramod Kumar, Anita Sharma, Bharadwaj TN, Dixit VP. Hypocholestrolemic activity of Marsilea minuta in gerbils. Fitoterapia 2000; 71:113-7. https://doi.org/10.1016/S0367-326X(99)00140-9
  12. Ghasi S, Nwobodo E, Ofili JO: Hypocholestrolemic effects of crude extract of leaf of Moringa oleifera Lam in high-fat diet fed Wistar rats. Journal of Ethnopharmacology. 2000; 69:21-5. https://doi.org/10.1016/S0378-8741(99)00106-3
  13. Yang MH, Wang CH, Chen HL. Green, oolong and black tea extracts modulate lipid metabolism in hyperlipidemia rats fed high-sucrose diet. J. of Nutritional Biochemistry 2001; 12:14-20. https://doi.org/10.1016/S0955-2863(00)00140-6
  14. Kim H, An JJ, Jo HK, Yoo HR, Seol IC, Kim YS. Experimental Study on the Effects of GamiSamgieum (SGMX) on Hyperlipidemia. The Journal of Korean Oriental Medicine. 2009; 30(3):86-97
  15. Mihara M, Uchiyama M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem. 1978; 86(1):271-8. https://doi.org/10.1016/0003-2697(78)90342-1
  16. Song YM, Kwon SU, Sung J, Ebrahim S, Smith GD, Sunwoo S, et al. Different risk factor profiles between subtypes of ischemic stroke. A case-control study in Korean men. Eur J Epidemiol. 2005; 20(7):605-12. https://doi.org/10.1007/s10654-005-6831-5
  17. Aronow WS. Management of hyperlipidemia with statins in the older patient. Clin Interv Aging. 2006; 1(4):433-8. https://doi.org/10.2147/ciia.2006.1.4.433
  18. Kesaniemi A. Cholesterol absorption inhibitors in the treatment of hyperlipidemia: clinical outcomes in large clinical trials. Fundam Clin Pharmacol. 2007; 21 Suppl 2:29-30.
  19. Alberts AW. Discovery, biochemistry and biology of lovastatin. Am J Cardiol. 1988; 62(15):10J-15J. https://doi.org/10.1016/0002-9149(88)90002-1
  20. Agrawal AR, Tandon M, Sharma PL. Effect of combining viscous fibre with lovastatin on serum lipids in normal human subjects. Int J Clin Pract. 2007; 61(11):1812-8. https://doi.org/10.1111/j.1742-1241.2007.01512.x
  21. Chrysohoou C, Singh S. Combination of a sterol absorption inhibitor and cardiovascular agents for the treatment of dyslipidemia. Recent Patents Cardiovasc Drug Discov. 2006; 1(1):73-8. https://doi.org/10.2174/157489006775244218
  22. Lim SM, An JJ, Choi Y, Oh BR, You HR, Kim YS, et al. The study on effects of Samgiyeum and Tobiyeum on thrombosis and brain damage. Korean J. Orient. Int. Med. 2002; 23(4):617-29.
  23. An JJ, Lim SM, Cho HG, Kim MS, You BC, Kim YJ, et al. Study on the Toxicity of Tobiyeum in rats. Korean J. Orient. Int. Med. 2002; 23(4):607-16.
  24. Kim SH, Seo SH, Choi IC, Woo YS, Yu YG, Kim JY, et al. The study on the effects of Tongbiyeum on essential thrombocythemia with cerebral infarction. Korean J. Orient. Int. Med. 2003; Autumn:42-8.
  25. Sekiya M, Hiraishi A, Touyama M, Sakamoto K. Oxidative stress induced lipid accumulation via SREBP1c activation in HepG2 cells. Biochem Biophys Res Commun. 2008; 375(4):602-7. https://doi.org/10.1016/j.bbrc.2008.08.068
  26. Uchida K. A lipid-derived endogenous inducer of COX-2: a bridge between inflammation and oxidative stress. Mol Cells. 2008; 25(3):347-51.
  27. Shin WT, Heo JE, Kim TH, Hong SH, Kwon OS, Kim KT, et al. Clinical effect of Dodam-tang on hyperlipidemia patients. J. Orient. Int. Med. 2007; fall:113-118.
  28. Kim BC, Lee EJ, Park CS, Park CG. The experimental study on the effects of Dansamyeum on hyperlipidemia. J. Orient. Int. Med. 2000; 21:126-34.
  29. Kim GY. Seo IB. Effects of SemyungGamiTang on the blood lipid in experimentally induced hyperlipidemic rabbits. J. Korean Oriental Med. 2000; 20(4):69-81.